세계의 의약품 중간체 CDMO 시장 : 용도별, 중간체 유형별, 의약품 유형별, 지역별 - 예측 분석(-2035년)

Global Pharmaceutical Intermediate CDMO Market Research Report by Application (Oncology, Cardiovascular Diseases, CNS & Neurological Disorders, Infectious Diseases), by Type of Intermediate [Active Pharmaceutical Ingredients (APIs), Excipients and Additives, Biologics Intermediates, Nucleotide Intermediates], by Drug Type (Generic Drugs, Branded Drugs), and by Region (North America, Europe, South America, Middle East and Africa, and Asia Pacific) Forecast Analysis till 2035

Industry Overview

In 2024, global pharmaceutical intermediate CDMO market was valued at USD 161,798.9 million. It is projected to increase at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2035, reaching USD 346,744.3 million.

The global market for Pharmaceutical Intermediate CDMOs is expanding rapidly due to various contributing factors. Outsourcing by pharmaceutical firms is on the rise as they aim to enhance efficiency and reduce operational burdens. The increasing need for generic drugs and biosimilars, especially in low- and middle-income countries, is a major growth driver. Additionally, advancements in intermediate synthesis technologies and the complex nature of new drug formulations are pushing companies toward specialized CDMO support. The growth of healthcare infrastructure in emerging economies is also enhancing the market landscape.

On the flip side, stringent regulatory compliance requirements and lengthy approval timelines often hamper progress. High capital and operational expenses, intellectual property-related risks, and ongoing supply chain disruptions present notable barriers. A shortage of expertise in advanced chemistry remains another challenge. Despite these issues, the market holds promising opportunities through strategic alliances with biotechnology companies and the increasing demand for tailored, patient-specific medicine solutions.

Industry Segmentations

In terms of application types, the global market is divided into oncology, cardiovascular diseases, CNS and neurological disorders, and infectious disease.

Based on the drug type, global pharmaceutical intermediate CDMO market comprises generic drugs, branded drug.

Global Pharmaceutical intermediate CDMO market has been categorized by type of intermediate, includes active pharmaceutical ingredients (APIS), biologics intermediates, excipients and additives, nucleotide intermediates.

Regionally, global pharmaceutical intermediate CDMO market divided into North America, Europe, South America, Middle East and Africa, and Asia Pacific.

Regional Analysis

The North American market for pharmaceutical intermediate CDMOs is the largest and most sophisticated, with the U.S. leading due to high-tech infrastructure, heavy R&D investments, and FDA-enforced quality regulations. Canada's rising biopharmaceutical industry further supports regional strength.

Europe caters to both domestic powerhouses and global players, emphasizing regulatory compliance, innovation in complex syntheses, and sustainable production practices aligned with circular economy principles.

Asia Pacific, spearheaded by China and India, is witnessing the fastest growth. Cost-effective manufacturing, large-scale facilities, and integrated supply chains enable competitive production of intermediates.

Latin America, while facing diverse regulatory frameworks across countries, is working toward unified standards through regional cooperation. Competitive labor costs and proximity to the U.S. are advantageous, though growth is somewhat hindered by infrastructure constraints.

In the Middle East and Africa, CDMOs largely serve local and neighboring markets by producing intermediates for generic medicines and essential drugs. The region's favorable location between Asia and Europe positions it as a potential hub in pharmaceutical logistics and intermediate supply. As global supply chains evolve, MEA's role may become more pronounced in bridging manufacturing efforts across continents.

Key Players

Thermo Fisher Scientific, Raghava Life Sciences Pvt LTD., Cambrex Corporation, Actylis, Chiracon GmbH, Codexis, Inc., Arkema S.A., Lonza Group AG, Catalent, Inc., Zhejiang Jiuzhou Pharmaceutical Co Ltd are the key competitors of the global pharmaceutical intermediate CDMO market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 MARKET OVERVIEW:
• 1.2 MARKET SEGMENTATION
• 1.3 COMPETITIVE LANDSCAPE
• 1.4 FUTURE OUTLOOK

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 Data Mining Process
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 Secondary Research Data Flow:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 Primary Research DATA FLOW:
  • 3.5.2 Primary Research: Number of Interviews conducted
  • 3.5.3 Primary Research: Regional Coverage
• 3.6 APPROACHES FOR MARKET END USER ESTIMATION:
  • 3.6.1 Revenue Analysis Approach
  • 3.6.2 Data forecasting
  • 3.6.3 Data Forecasting Technique
• 3.7 DATA MODELING
  • 3.7.1 microeconomic factor analysis:
  • 3.7.2 Data modeling:
• 3.8 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 Increasing Outsourcing by Pharmaceutical Companies
  • 4.2.2 Rising Demand for Generic Drugs and Biosimilars
  • 4.2.3 Technological Advancements in Intermediate Synthesis
  • 4.2.4 Growing Complexity of Drug Molecules
  • 4.2.5 Expansion in Emerging Markets
• 4.3 RESTRAINTS
  • 4.3.1 Stringent Regulatory Compliance and Complex Approval Processes
  • 4.3.2 High Operational and Capital Expenditure Costs
  • 4.3.3 Property (IP) Risks and Confidentiality Concerns
  • 4.3.4 Supply Chain Disruptions and Raw Material Shortages
  • 4.3.5 Limited Expertise in Advanced Technologies and Niche Chemistry
• 4.4 OPPORTUNITY
  • 4.4.1 Strategic Partnerships with Biotech Firms
  • 4.4.2 Focus on Personalized Medicine Solutions
• 4.5 IMPACT ANALYSIS OF COVID - 19

5 MARKET FACTOR ANALYSIS

• 5.1 SUPPLY CHAIN ANALYSIS
  • 5.1.1 Raw Material Sourcing & Procurement
  • 5.1.2 Research, Development, & Process Optimization
  • 5.1.3 Manufacturing & Quality Control
  • 5.1.4 Packaging, Storage, & Logistics & Distribution & Customer Delivery
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 Threat of New Entrants (Low to Moderate)
  • 5.2.2 Bargaining Power of Suppliers (Moderate)
  • 5.2.3 Threat of Substitutes (Low to Moderate)
  • 5.2.4 Bargaining Power of Buyers (High)
  • 5.2.5 Intensity of Rivalry (High)

6 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE

• 6.1 INTRODUCTION
• 6.2 ACTIVE PHARMACEUTICAL INGREDIENTS (APIS)
• 6.3 EXCIPIENTS & ADDITIVES

7 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE

• 7.1 INTRODUCTION
• 7.2 GENERIC DRUGS
• 7.3 BRANDED DRUGS

8 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 ONCOLOGY
• 8.3 CARDIOVASCULAR DISEASES
• 8.4 CNS & NEUROLOGICAL DISORDERS
• 8.5 INFECTIOUS DISEASES
• 8.6 OTHERS

9 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION

• 9.1 GLOBAL
• 9.2 NORTH AMERICA
  • 9.2.1 USA
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 united kingdom
  • 9.3.2 germany
  • 9.3.3 france
  • 9.3.4 italy
  • 9.3.5 spain
  • 9.3.6 RUSSIA
  • 9.3.7 rest of europe
• 9.4 ASIA PACIFIC
  • 9.4.1 china
  • 9.4.2 South Korea
  • 9.4.3 indiA
  • 9.4.4 Japan
  • 9.4.5 indonesia
  • 9.4.6 malaysia
  • 9.4.7 thailand
  • 9.4.8 rest of asia pacific
• 9.5 SOUTH AMERICA
  • 9.5.1 Mexico
  • 9.5.2 Brazil
  • 9.5.3 argentina
  • 9.5.4 rest of south america
• 9.6 MIDDEL EAST AND AFRICA
  • 9.6.1 gcc countries
  • 9.6.2 south africa
  • 9.6.3 rest of middle east & africa

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 MARKET SHARE ANALYSIS, 2024SS
• 10.3 COMPETITOR DASHBOARD

11 COMPANY PROFILES

• 11.1 RAGHAVA LIFE SCIENCES PVT LTD
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 Key Development
  • 11.1.3 SWOT ANALYSIS
  • 11.1.4 Key Strategy
• 11.2 ACTYLIS
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 PRODUCT OFFERED
  • 11.2.3 Key Development
  • 11.2.4 SWOT ANALYSIS
  • 11.2.5 Key Strategy
• 11.3 CHIRACON GMBH
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 PRODUCT OFFERED
  • 11.3.3 SWOT ANALYSIS
  • 11.3.4 Key Strategy
• 11.4 CODEXIS, INC.
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 PRODUCT OFFERED
  • 11.4.3 Key Development
  • 11.4.4 SWOT ANALYSIS
  • 11.4.5 financial analysis
  • 11.4.6 Key Strategy
• 11.5 ARKEMA S.A.
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 PRODUCT OFFERED
  • 11.5.3 SWOT ANALYSIS
  • 11.5.4 financial analysis
  • 11.5.5 Key Strategy
• 11.6 LONZA GROUP AG
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 PRODUCT OFFERED
  • 11.6.3 Key Development
  • 11.6.4 SWOT ANALYSIS
  • 11.6.5 financial analysis
  • 11.6.6 Key Strategy
• 11.7 THERMO FISHER SCIENTIFIC (PATHEON)
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 PRODUCT OFFERED
  • 11.7.3 Key Development
  • 11.7.4 SWOT ANALYSIS
  • 11.7.5 financial analysis
  • 11.7.6 Key Strategy
• 11.8 CAMBREX CORPORATION
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 PRODUCT OFFERED
  • 11.8.3 Key Development
  • 11.8.4 SWOT ANALYSIS
  • 11.8.5 Key Strategy
• 11.9 CATALENT, INC.
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 PRODUCT OFFERED
  • 11.9.3 Key Development
  • 11.9.4 SWOT ANALYSIS
  • 11.9.5 financial analysis
  • 11.9.6 Key Strategy
• 11.10 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 PRODUCT OFFERED
  • 11.10.3 Key Development
  • 11.10.4 SWOT ANALYSIS
  • 11.10.5 financial analysis
  • 11.10.6 Key Strategy